ArticleAntimicrobial agents and chemotherapy1996
Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery.
Article in Antimicrobial agents and chemotherapy, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 60 citations in OpenAlex.
- Design and synthesis of natural antibacterial derivatives for ocular tuberculosis: a comprehensive review.Frontiers in pharmacology · 2025Review
- A Fluorescent Reporter-Based Evaluation Assay for Antibacterial Components AgainstFrontiers in microbiology · 2022Article
- Early detection and classification of live bacteria using time-lapse coherent imaging and deep learning.Light, science & applications · 2020Article
- Rapid Tuberculosis Diagnosis Using Reporter Enzyme Fluorescence.Journal of clinical microbiology · 2019Article
- Hit Generation in TB Drug Discovery: From Genome to Granuloma.Chemical reviews · 2018Review
- Intravital excitation increases detection sensitivity for pulmonary tuberculosis by whole-body imaging with β-lactamase reporter enzyme fluorescence.Journal of biophotonics · 2017Article
- Reporter-Based Assays for High-Throughput Drug Screening againstFrontiers in microbiology · 2017Article
- A Fluorescent Probe for DetectingFrontiers in microbiology · 2016Article
- Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2015Article
- Simple and rapid method to determine antimycobacterial potency of compounds by using autoluminescent Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2014Article
- Article
- Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase.The Journal of antimicrobial chemotherapy · 2013Article
- Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence.The Journal of antimicrobial chemotherapy · 2012Article
- Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy.PloS one · 2012Article
- Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains.Antimicrobial agents and chemotherapy · 2010Article
- Article
- Improved green fluorescent protein reporter gene-based microplate screening for antituberculosis compounds by utilizing an acetamidase promoter.Antimicrobial agents and chemotherapy · 2003Article
- Simple fibroblast-based assay for screening of new antimicrobial drugs against Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2002Article
- Rapid screening method for Mycobactericidal activity of chemical germicides that uses Mycobacterium terrae expressing a green fluorescent protein gene.Applied and environmental microbiology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bioluminescence-based assays to indicate antimicrobial susceptibility have been developed and validated for recombinant strains of Mycobacterium tuberculosis, Mycobacterium bovis BCG, Mycobacterium avium, and Mycobacterium intracellulare expressing an integrated eukaryotic luciferase gene. MICs determined with these bioluminescence assays for several antimycobacterial agents, including isoniazid, ethambutol, rifampin, amikacin, streptomycin, ciprofloxacin, and clarithromycin, compared favorably with traditional BACTEC methods and visual estimations of the inhibitory end point. Assay methodology has been optimized for the analysis of large numbers of novel compounds and is simple, inexpensive, and labor efficient. The availability of these four recombinant mycobacteria has permitted a strategy for drug discovery employing the nonpathogenic BCG strain for mass screening purposes with subsequent confirmation of activity against the pathogenic mycobacteria. Furthermore, evidence suggests that the BCG-based screen may allow the direct identification of bactericidal agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.